189 related articles for article (PubMed ID: 24824093)
21. [DRUGS DESENSITIZATION].
Hacard F; Bérard F
Rev Prat; 2015 Sep; 65(7):986-9. PubMed ID: 26619741
[TBL] [Abstract][Full Text] [Related]
22. Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
Vivas AC; Chimento SM; Herschthal J; Spock C; Alonso-Llamazares J
J Am Acad Dermatol; 2013 Jun; 68(6):e179-80. PubMed ID: 23680209
[No Abstract] [Full Text] [Related]
23. Case of angioedema and urticaria induced by lenalidomide.
Uchiyama A; Motegi S; Yamada K; Uehara A; Ishikawa O
J Dermatol; 2014 Feb; 41(2):179-81. PubMed ID: 24387621
[No Abstract] [Full Text] [Related]
24. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
[TBL] [Abstract][Full Text] [Related]
25. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
Intern Med; 2014; 53(15):1651-3. PubMed ID: 25088880
[TBL] [Abstract][Full Text] [Related]
26. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Zamarin D; Devlin SM; Arcila ME; Landau H; Lesokhin A; Lendvai N; Chung DJ; Chimento D; Weltz J; Babu D; Giralt S; Hassoun H
Leukemia; 2013 Dec; 27(12):2422-4. PubMed ID: 23608883
[No Abstract] [Full Text] [Related]
27. Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission.
Kootte RS; Faber LM
Neth J Med; 2017 Apr; 75(3):117-121. PubMed ID: 28469048
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
Ying L; YinHui T; Yunliang Z; Sun H
Oncotarget; 2017 Jul; 8(28):46593-46600. PubMed ID: 28423741
[TBL] [Abstract][Full Text] [Related]
29. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Dasanu CA; Bockorny B; Alexandrescu DT
J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
[TBL] [Abstract][Full Text] [Related]
30. Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
Sakai M; Kubota T; Takaoka M; Tsukuda T; Arakawa Y; Anabuki K; Ikezoe T; Togitani K; Yokoyama A
Ann Hematol; 2015 May; 94(5):891-2. PubMed ID: 25407112
[No Abstract] [Full Text] [Related]
31. Pomalidomide in the treatment of relapsed multiple myeloma.
Forsberg PA; Mark TM
Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
[TBL] [Abstract][Full Text] [Related]
32. Delayed Cutaneous Hypersensitivity Reactions to Antibiotics: Management with Desensitization.
McNulty CMG; Park MA
Immunol Allergy Clin North Am; 2017 Nov; 37(4):751-760. PubMed ID: 28965638
[TBL] [Abstract][Full Text] [Related]
33. Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?
Kreiniz N; Khateeb A; Gino-Moor S; Polliack A; Tadmor T
Anticancer Res; 2016 Jun; 36(6):2889-92. PubMed ID: 27272801
[TBL] [Abstract][Full Text] [Related]
34. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group.
Scherer K; Brockow K; Aberer W; Gooi JH; Demoly P; Romano A; Schnyder B; Whitaker P; Cernadas JS; Bircher AJ;
Allergy; 2013 Jul; 68(7):844-52. PubMed ID: 23745779
[TBL] [Abstract][Full Text] [Related]
35. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous adverse reactions to lenalidomide.
Imbesi S; Allegra A; Calapai G; Musolino C; Gangemi S
Allergol Immunopathol (Madr); 2015; 43(1):88-91. PubMed ID: 24998775
[TBL] [Abstract][Full Text] [Related]
37. Successful rapid push subcutaneous desensitization in a patient with delayed local hypersensitivity reactions to immunoglobulins.
Ghurye RR; Bright P; Lowe D; Buckland MS
J Allergy Clin Immunol Pract; 2019; 7(8):2906-2908. PubMed ID: 31102702
[No Abstract] [Full Text] [Related]
38. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Gavriatopoulou M; Kastritis E; Ntanasis-Stathopoulos I; Fotiou D; Roussou M; Migkou M; Ziogas DC; Kanellias N; Terpos E; Dimopoulos MA
Blood; 2018 Jan; 131(4):464-467. PubMed ID: 29167176
[No Abstract] [Full Text] [Related]
39. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Kuroda J; Kobayashi T; Taniwaki M
Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
[TBL] [Abstract][Full Text] [Related]
40. Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma.
Kiesewetter B; Raderer M
Leuk Lymphoma; 2015 Feb; 56(2):548-9. PubMed ID: 25120052
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
